ClinicalTrials.gg
WithdrawnNCT05644925PiCSO-STEMIUpdated Aug 14, 2025

Effects of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) Therapy on miRNAs Expression and Absolute Microvascular Resistance by Continuous Thermodilution in ST-segment Elevation Myocardial Infarction (STEMI) Patients: PiCSO-STEMI TRIAL

An interventional study of PiCSO Impulse System and Percutaneous Coronary Intervention (PCI) in Anterior Myocardial Infarction, sponsored by Fundacio Privada Mon Clinic Barcelona. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Fundacio Privada Mon Clinic Barcelona · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Lack of financial support for recruitment and follow-up activities.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In this study we pretend to determine the molecular (miRNAs expression, angiogenic and inflammatory biomarkers) and microcirculatory (assessed by the innovative continuous intracoronary thermodilution technique) effects of PiCSO compared to a standard PCI control group in patients with high-risk anterior STEMI. Then, we aim to assess the efficacy of these molecular biomarkers as prognostic tools. Also, we will evaluate the impact of PiCSO on the coronary microcirculation beyond the acute phase in the follow-up six months after STEMI. Finally, we will assess PiCSO influence on Heart Failure (HF) clinical variables and patients' quality of life including a cost-effectiveness assessment in the mid-term follow-up one year after the STEMI event.

02

Conditions studied

  • Anterior Myocardial Infarction
03

In context

Anterior Wall Myocardial Infarction

36 studies on the registry are indexed under Anterior Wall Myocardial Infarction; 5 are open to participants now.

Browse Anterior Wall Myocardial Infarction studies →

Lead sponsor

Fundacio Privada Mon Clinic Barcelona is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Anterior STEMI ( with persistent elevation ≥ 2 mm (0.2 mV) in 2 or more contiguous anterior precordial leads (V2, V3, V4) in men or ≥ 1.5 mm (0.15 mV) in women.
  3. Culprit lesion in proximal or mid Left Anterior Descending Artery (LAD).
  4. Pre-PCI TIMI flow 0-1.
  5. Symptoms consistent with myocardial ischemia (persistent chest pain, dyspnea, nauseas/vomiting, fatigue, palpitations or syncope) present for ≤ 12 hours.
  6. The patient is eligible for primary PCI.
  7. received and signed for study enrollment.

Exclusion criteria

Exclusion Criteria:

  1. to coronary angiogram or PCI.
  2. Implants or foreign bodies in the coronary sinus.
  3. Known allergies to polyurethanes, Polyethylene Terephthalate (PET) or stainless steel.
  4. Known pregnancy or breastfeeding.
  5. Known coagulopathy.
  6. Known severe kidney disease ( \<=30 mL/min/1.73) and/or hemodialysis.
  7. Known large pericardial effusion or cardiac tamponade.
  8. Central hemodynamically relevant left-right shunt.
  9. Previous MI or Coronary Artery Bypass Graft (CABG).
  10. Previous history of stroke, (TIA) or reversible ischemic neurological deficit within last 6 months.
  11. Cardiopulmonary resuscitated (CPR) cardiac arrest ≥ 5 minutes whom baseline neurologic status is not present.
  12. Unconscious at presentation.
  13. Need for circulatory support.
  14. Need for invasive mechanical ventilation.
  15. Need for temporal intravenous pacemaker.
  16. Patient not suitable for femoral access.
  17. Known contraindication for adenosine administration (severe asthma, complicated Atrioventricular (AV) block, critical aortic stenosis, severe cardiac arrhythmias, severe valve diseases).
  18. Known epicardial stenosis greater than 50% distal to the culprit LAD lesion.
  19. Active participation in another drug or device trial.
  20. Medical, social or psychological condition that limits the ability of patient to participate in the study.
  21. Patients with definite or probable coronavirus disease 19 diagnosis within 2 weeks prior to STEMI.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    PICSO+PCI

    Device: PiCSO Impulse System · Procedure: Percutaneous Coronary Intervention (PCI)

  • Active comparator
    Standard PCI

    Procedure: Percutaneous Coronary Intervention (PCI)

Interventions

  • DevicePiCSO Impulse System

    The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.

  • ProcedurePercutaneous Coronary Intervention (PCI)

    Minimally invasive procedures used to open clogged coronary arteries

06

What researchers measure

Primary outcomes

  1. Superiority of PiCSO in reducing microvascular dysfunction

    To determine the superiority of PiCSO in reducing the microvascular dysfunction (defined as microvascular resistance \>500 WU) as compared to standard of care

    Time frame: After primary PCI at time 0 after intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jun 2024, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 9, 2022
StartActual
Nov 14, 2022
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05644925
Lead sponsor
Fundacio Privada Mon Clinic Barcelona
Collaborators
Miracor Medical SA
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Nov 14, 2022
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Last update
Aug 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion